المؤلفون: Turner, N. C.

المساهمون: Koeck, Richard, Jackson, Iain

مصطلحات موضوعية: 791.4302

الوصول الحر: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.762782Test

المؤلفون: Gennari, A., Andre, F., Barrios, C. H., Cortes, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., Im, S. -a., Krug, D., Kunz, W. G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H. S., Saura, C., Schmid, P., Singer, C. F., Spanic, T., Tolaney, S. M., Turner, N. C., Curigliano, G., Loibl, S., Paluch-Shimon, S., Harbeck, N., ESMO Guidelines Committee

المساهمون: 임석아, Im, S. -a.

مصطلحات موضوعية: INTERNATIONAL CONSENSUS GUIDELINES, ALPELISIB PLUS FULVESTRANT, GERMLINE BRCA MUTATION, DOUBLE-BLIND, OPEN-LABEL, PHYSICIANS CHOICE, SACITUZUMAB GOVITECAN, TRASTUZUMAB EMTANSINE, REPORTED OUTCOMES, ENDOCRINE THERAPY, diagnosis, ESCAT, ESMO Clinical Practice Guideline, ESMO-MCBS, metastatic breast cancer, treatment

العلاقة: Annals of Oncology, Vol.32 No.12, pp.1475-1495; 153495; https://hdl.handle.net/10371/179242Test; 000721610600008; 2-s2.0-85120812833

الإتاحة: https://doi.org/10.1016/j.annonc.2021.09.019Test
https://hdl.handle.net/10371/179242Test

المؤلفون: Pascual, J, Attard, G, Bidard, F-C, Curigliano, G, De Mattos-Arruda, L, Diehn, M, Italiano, A, Lindberg, J, Merker, J D, Montagut, C, Normanno, N, Pantel, K, Pentheroudakis, G, Popat, S, Reis-Filho, J S, Tie, J, Seoane, J, Tarazona, N, Yoshino, T, Turner, N C

مصطلحات موضوعية: circulating tumour DNA (ctDNA), liquid biopsy, precision medicine, Biomarkers, Tumor, Circulating Tumor DNA, Humans, Mutation, Neoplasm Recurrence, Local

العلاقة: http://hdl.handle.net/10668/21915Test; http://www.annalsofoncology.org/article/S0923753422017215/pdfTest

الإتاحة: https://doi.org/10.1016/j.annonc.2022.05.520Test
http://hdl.handle.net/10668/21915Test
http://www.annalsofoncology.org/article/S0923753422017215/pdfTest

المؤلفون: Gennari A., Andre F., Barrios C. H., Cortes J., de Azambuja E., DeMichele A., Dent R., Fenlon D., Gligorov J., Hurvitz S. A., Im S. -A., Krug D., Kunz W. G., Loi S., Penault-Llorca F., Ricke J., Robson M., Rugo H. S., Saura C., Schmid P., Singer C. F., Spanic T., Tolaney S. M., Turner N. C., Curigliano G., Loibl S., Paluch-Shimon S., Harbeck N.

المساهمون: A. Gennari, F. Andre, C.H. Barrio, J. Corte, E. de Azambuja, A. Demichele, R. Dent, D. Fenlon, J. Gligorov, S.A. Hurvitz, S.-. Im, D. Krug, W.G. Kunz, S. Loi, F. Penault-Llorca, J. Ricke, M. Robson, H.S. Rugo, C. Saura, P. Schmid, C.F. Singer, T. Spanic, S.M. Tolaney, N.C. Turner, G. Curigliano, S. Loibl, S. Paluch-Shimon, N. Harbeck

مصطلحات موضوعية: diagnosi, ESCAT, ESMO Clinical Practice Guideline, ESMO-MCBS, metastatic breast cancer, treatment, Female, Human, Medical Oncology, Breast Neoplasms, Settore MED/06 - Oncologia Medica

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34678411; info:eu-repo/semantics/altIdentifier/wos/WOS:000721610600008; volume:32; issue:12; firstpage:1475; lastpage:1495; numberofpages:21; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/910168Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85120812833

الإتاحة: https://doi.org/10.1016/j.annonc.2021.09.019Test
http://hdl.handle.net/2434/910168Test

المؤلفون: Okines, A. F. C., Braybrooke, J., MacPherson, I. R., Sutherland, S., Howell, Sacha J, Wheatley, D., Waters, S., Roylance, R., Baird, R. D., Oikonomidou, O., Palmieri, C., Harries, M., Harper-Wynne, C., Sheri, A., Khan, S., Bunce, C., Mohammed, K., Lee, D., Turner, N. C.

المساهمون: The Royal Marsden NHS Foundation Trust, London

العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS1111Test; Okines AFC, Braybrooke J, MacPherson IR, Sutherland S, Howell SJ, Wheatley D, et al. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005533.; http://hdl.handle.net/10541/626668Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1111Test
http://hdl.handle.net/10541/626668Test

المؤلفون: Rugo, H. S., Oliveira, M., Howell, Sacha J, Dalenc, F., Cortes, J., Gomez, H. L., Hu, X. C., Iwata, H., Jhaveri, K. L., Loibl, S., Murillo, S. M., Okera, M., Park, Y. H., Sohn, J., Zhukova, L., Logan, J., Twomey, K., Khatun, M., D'Cruz, C. M., Turner, N. C.

المساهمون: University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco

العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1067Test; Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000178.; http://hdl.handle.net/10541/626633Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2023.41.16_suppl.1067Test
http://hdl.handle.net/10541/626633Test

المؤلفون: Hui R., Pearson A., Cortes J., Campbell C., Poirot C., Azim H. A., Fumagalli D., Lambertini M., Daly F., Arahmani A., Perez-Garcia J., Aftimos P., Bedard P. L., Xuereb L., Scheepers E. D., Vicente M., Goulioti T., Loibl S., Loi S., Pierrat M. -J., Turner N. C., Andre F., Curigliano G.

المساهمون: R. Hui, A. Pearson, J. Corte, C. Campbell, C. Poirot, H.A. Azim, D. Fumagalli, M. Lambertini, F. Daly, A. Arahmani, J. Perez-Garcia, P. Aftimo, P.L. Bedard, L. Xuereb, E.D. Scheeper, M. Vicente, T. Goulioti, S. Loibl, S. Loi, M.-. Pierrat, N.C. Turner, F. Andre, G. Curigliano

مصطلحات موضوعية: Adult, Aged, Biomarkers, Tumor, Breast Neoplasm, Estrogen Receptor alpha, Female, Gene Amplification, Human, Middle Aged, Molecular Targeted Therapy, Naphthalene, Neoplasm Metastasi, Patient Safety, Protein Kinase Inhibitor, Quinoline, Receptor, ErbB-2, Fibroblast Growth Factor, Type 1, Receptors, Progesterone, Treatment Outcome, Settore MED/06 - Oncologia Medica

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31619444; info:eu-repo/semantics/altIdentifier/wos/WOS:000507311000006; volume:26; issue:2; firstpage:354; lastpage:363; numberofpages:10; journal:CLINICAL CANCER RESEARCH; http://hdl.handle.net/2434/824444Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076132296

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-19-1164Test
http://hdl.handle.net/2434/824444Test

المؤلفون: Bolger, T. P., Turner, N. C.

المصدر: Oecologia, 1998 Jan 01. 115(1/2), 32-38.

الوصول الحر: https://www.jstor.org/stable/4221976Test

المؤلفون: Turner, N. C., Laird, A. D., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E. M., Mina, L. A., Balmaña, J., Fasching, P. A., Hurvitz, S. A., Hopkins, J. F., Albacker, L. A., Chelliserry, J., Chen, Y., Conte, U., Wardley, Andrew M, Robson, M. E.

المساهمون: The Royal Marsden Hospital, The Institute of Cancer Research, London, UK

العلاقة: https://dx.doi.org/10.1038/s41523-023-00561-yTest; Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer. 2023 Oct 6;9(1):81. PubMed PMID: 37803017. Pubmed Central PMCID: PMC10558443 financial interests: advisory board honoraria from AstraZeneca, Exact Sciences, Gilead Sciences, GSK, Guardant, Inivata, Lilly, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, Roche/Genentech, and Zentalis; and research funding from AstraZeneca, Guardant Health, Inivata, Invitae, Merck Sharp & Dohme, Natera, Personalis, Pfizer, and Roche/Genentech. ADL, JC, and UC declare no competing non-financial interests but the following competing financial interests: employees of Pfizer and own stocks in Pfizer. MLT declares no competing non-financial interests but the following competing financial interests: research funding (to her institution) from AbbVie, Arvinas, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GSK, Hummingbird Biosciences, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro and Vertex; and consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Gilead Sciences, GSK, G1 Therapeutics, Guardant, Immunomedics, Merck, Natera, Novartis, OncoSec, Pfizer, RefleXion, Replicate, Roche/Genentech, and Sanofi. HSR declares no competing non-financial interests but the following competing financial interests: research support to the University of California San Francisco from Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Lilly, Merck & Co., Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Roche/Genentech, Sermonix Pharmaceuticals, Taiho Oncology, and Veru; travel support to academic meetings from AstraZeneca, Gilead Sciences, and Merck; and consultancy/advisory support from Blueprint, NAPO, Puma, and Scorpion Therapeutics. AM declares no competing non-financial interests but the following competing financial interests: honoraria from Pfizer, and travel/accommodation support from AstraZeneca and Pierre Fabre. JE declares no competing non-financial interests but the following competing financial interests: consulting fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Tesaro; contracted research from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Odonate, Pfizer, Roche, and Seattle Genetics; and travel support from AstraZeneca, Celgene, Daiichi Sankyo, Lilly, Novartis, Pfizer, and Tesaro. E-MG and LAM have nothing to disclose. JB declares no competing non-financial interests but the following competing financial interests: consultant/advisory board member for AstraZeneca and Pfizer; and submitted a European patent request (EP17382884.9). PAF declares no competing non-financial interests but the following competing financial interests: commercial research grants from Novartis to his institution; speakers bureau honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva; and consultant/advisory board member for Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva. SAH declares the following non-financial interests: unpaid TRIO-US Chief Medical Officer (until Jan 2023), unpaid consultant/steering committee member for Arvinas, AstraZeneca, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Gilead Sciences, Greenwich Life Sciences, Immunomedics, Lilly, MacroGenics, Novartis, Orum, Pieris Pharmaceuticals, Puma Biotechnology, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, Zymeworks; and the following competing financial interests: contracted research support (which may include editorial assistance) from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, BioMarin, Cascadian Therapeutics, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Dignitana, G1 Therapeutics, Gilead Sciences, Greenwich Life Sciences, GSK, Immunomedics, Lilly, MacroGenics, Merrimack, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Design, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, and Zymeworks. JFH was an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG when the study was carried out. LAA declares no competing non-financial interests but the following competing financial interests: employee of Foundation Medicine, Inc. and owns stocks in Roche Holdings AG. YC declares no competing non-financial interests but the following competing financial interests: contractor at Pfizer (until 2021) at the time the work was performed. AMW declares no competing non-financial interests but the following competing financial interests (at the time of the study): consultancy fees from ACCORD, Amgen, AstraZeneca, Athenex, Daiichi Sankyo, Lilly, MSD, NAPP, Novartis, Pfizer, Pierre Fabre, Roche, and Takeda; reimbursement from Amgen, Daiichi Sankyo, and Roche; speaker fees from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; and research funding from Lilly, Novartis, Pfizer, and Roche. He was NCRI Breast Research Group early breast cancer systemic anti-cancer therapy lead 2014–21, ACP strategy director 2018–21, and a member of NHSE Clinical reference group for systemic anti-cancer therapy 2013–21 and clinical advisor to NICE for same period (all unremunerated). He left the NHS in January 2021 and worked for AstraZeneca until March 2022, when he left to concentrate fulltime on Outreach Research & Innovation Group (a company he founded to improve access to clinical trials for cancer patients). He has given talks for Roche and Seagen separately through Andrew Wardley Limited. MER declares no competing non-financial interests but the following competing financial interests: research funding from AstraZeneca and Pfizer; past research funding from AbbVie, Medivation, and Tesaro (at the time the work was performed); travel, accommodation, and expenses from AstraZeneca and other transfer of value from AstraZeneca and Pfizer. Epub 2023/10/07. eng.; http://hdl.handle.net/10541/626610Test; NPJ Breast Cancer

الإتاحة: https://doi.org/10.1038/s41523-023-00561-yTest
http://hdl.handle.net/10541/626610Test

المؤلفون: Turner, N. C., Oliveira, M., Howell, Sacha J, Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., Morales Murillo, S., Okera, M., Park, Y. H., Sohn, J., Toi, M., Tokunaga, E., Yousef, S., Zhukova, L., de Bruin, E. C., Grinsted, L., Schiavon, G., Foxley, A., Rugo, H. S.

المساهمون: Royal Marsden Hospital, Institute of Cancer Research, London

العلاقة: https://dx.doi.org/10.1056/NEJMoa2214131Test; Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2023 Jun 1;388(22):2058-70. PubMed PMID: 37256976. Epub 2023/05/31. eng.; http://hdl.handle.net/10541/626338Test; New England Journal of Medicine

الإتاحة: https://doi.org/10.1056/NEJMoa2214131Test
http://hdl.handle.net/10541/626338Test